Kunasan

Kunasan operates at the intersection of neurotechnology, medical devices, and sleep health. Its stated focus is non-invasive neuromodulation during sleep, with an emphasis on autonomic and thalamocortical network activity and slow-wave sleep continuity. The company identifies FREQUEN-ZZZ and DeltaWave TVMS as investigational platforms; one is described as using low-intensity radiofrequency gradients, while the other is under clinical evaluation for autonomic network regulation. This gives Kunasan a device- and mechanism-oriented profile rather than a general sleep-tracking or wellness proposition. The distinction that can be described is its intended intervention: non-contact electromagnetic modulation during sleep, rather than simply measuring or reporting sleep. Its categories also place it across therapeutics, medical devices, neuroscience, and wearables.

Its current profile describes a small organization, with an employee-size range of 1–10. The clearest identifiable inflection point is Dr. Dan Gartenberg’s appointment as Chief Scientist in March 2025, which signals a scientific leadership addition but does not by itself establish a change in hiring pace or operating scale. Product development centers on two investigational platforms: FREQUEN-ZZZ, designed to use low-intensity radiofrequency gradients to modulate vagal networks, and DeltaWave TVMS, being evaluated for autonomic network regulation during sleep. The evidence supports a research-led development trajectory, but not a quantified growth trend. Future assessment will depend on demonstrable clinical findings, product milestones, and evidence of expansion beyond the reported small employee range.